{"text": ["Novartis", "Plans", "to", "Launch", "RTH258", "in", "2019", "to", "Treat", "nAMD"], "created_at": "2018-02-20 22:16:41"}
{"text": ["Wedbush:", "Restorbio's", "Therapy", "For", "Aging-Related", "Diseases", "Has", "Best-In-Class", "Potential"], "created_at": "2018-02-20 19:39:10"}
{"text": ["Incyte", "(INCY)", "Q4", "2017", "Earnings", "Conference", "Call", "Transcript"], "created_at": "2018-02-20 17:27:52"}
{"text": ["Novartis", "Seeks", "to", "Acquire", "Advanced", "Accelerator", "Applications"], "created_at": "2018-02-20 15:31:16"}
{"text": ["Novartis", "Psoriasis", "Drug", "Cosentyx", "Positive", "in", "SCALP", "Study"], "created_at": "2018-02-20 15:11:31"}
{"text": ["Novartis", "Psoriasis", "Drug", "Cosentyx", "Positive", "in", "SCALP", "Study"], "created_at": "2018-02-20 15:11:31"}
{"text": ["GlaxoSmithKline\u2019s", "Vaccines", "Business", "in", "4Q17"], "created_at": "2018-02-20 14:02:40"}
{"text": ["Promacta", "and", "Jakavi", "May", "Boost", "Novartis\u2019s", "Oncology", "Segment", "Revenues"], "created_at": "2018-02-20 14:02:06"}
{"text": ["Novartis", "Psoriasis", "Drug", "Cosentyx", "Positive", "in", "SCALP", "Study"], "created_at": "2018-02-20 13:27:01"}
{"text": ["Today\u2019s", "Research", "Reports", "on", "Trending", "Tickers:", "UnitedHealth", "Group", "and", "Novartis"], "created_at": "2018-02-20 13:00:00"}
{"text": ["GlaxoSmithKline\u2019s", "Global", "Pharmaceuticals", "Business", "in", "4Q17"], "created_at": "2018-02-20 12:32:24"}
{"text": ["Kisqali:", "Therapy", "for", "Advanced", "Breast", "Cancer", "in", "Premenopausal", "Women"], "created_at": "2018-02-20 12:31:34"}
{"text": ["The", "Swiss", "Stock", "Market", "Climbed", "On", "Strength", "Of", "Financials"], "created_at": "2018-02-20 12:07:00"}
{"text": ["The", "Swiss", "Stock", "Market", "Climbed", "On", "Strength", "Of", "Financials"], "created_at": "2018-02-20 12:07:00"}
